Lv41
410 积分 2022-06-16 加入
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
17天前
已完结
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
1个月前
已完结
Opportunities and limitations of B cell depletion approaches in SLE
1个月前
已完结
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
1个月前
已完结
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
1个月前
已完结
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
1个月前
已关闭
Flow Cytometry and Pharmacokinetics
1个月前
已完结
A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma
3个月前
已关闭
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B‐cell lineage neoplasms
3个月前
已完结
Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy
3个月前
已完结
皖公网安备34019202002308
